Mar 4, 2020 · Participants in the long-acting–therapy group received oral lead-in therapy with cabotegravir (CAB) plus rilpivirine (RPV), followed by injections of long-acting formulations: initial loading ...

In January 2021, the U.S. Food and Drug Administration (FDA) approved the use of cabotegravir–rilpivirine (CAB/RPV), the first injectable long-acting antiretroviral therapy (LA ART), for people living with HIV (PLWH; Bernstein, 2021; NIH, 2021).

May 25, 2024 · Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency virus type 1 virologic suppression. Across the phase 3/3b trials, the most frequently reported adverse events were injection site reactions (ISRs).

Mar 8, 2024 · Cabenuva is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and adolescents 12 years of age and older who weigh at least 77 lb (35 kg) and who meet certain requirements, as determined by a health care provider.

To the Editor Long-acting injectable cabotegravir and rilpivirine (CAB-RPV) is approved for people with HIV who have viral suppression with oral antiretroviral therapy (ART), no known or suspected resistance to either drug, and no chronic hepatitis B.

Feb 18, 2021 · Tolerability to CAB and RPV should be assessed using an oral lead-in of CAB 30 mg plus RPV 25 mg once daily with food for at least 28 days before beginning the IM injections.

Cabotegravir + rilpivirine long-acting (CAB + RPV LA) injectable is the first complete long-acting antiretroviral therapy (ART) regimen approved for the treatment of HIV-1 in the US.

CAB-LA and RPV-LA, given as separate intramuscular injections. On 18 November 2021, after several delays, NICE announced the long-awaited decision to approve an injectable HIV combination that is given every two months.

Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CAB+RPV long-acting administered every 2 months (Q2M) in adults living ...

Jan 1, 2025 · Creating programs that can support PWH with adherence challenges, their providers, and their clinics to use LA-CAB/RPV in service of sustained viral suppression is an urgent priority, particularly for PWH with CD4+ cell count <200 cells/mm3.